River Cities Capital

River Cities Capital Funds has spent nearly three decades perfecting one thing: identifying healthcare companies that can genuinely improve patient outcomes while building category-leading businesses Understanding healthcare financial benchmarks helps founders navigate this. Founded in 1994 and headquartered in Cincinnati with a second office in Raleigh, North Carolina, RC Capital has grown from an early-stage investor into a sophisticated growth equity firm with over 100 investments and 46 successful exits under its belt.

In mid-2023, the firm closed its seventh and largest fund to date — River Cities Fund VII at $242 million with a target of $300 million at final close. That capital will support RC Capital's continued focus on medical devices, healthcare services, and healthcare IT companies at the growth stage. This is not a firm that spreads thin across sectors; every investment flows through those three verticals, and the firm's thesis centers on what they call being "on the right side of healthcare."

For founders building in healthcare, understanding how RC Capital thinks about deals — their criteria, their portfolio, their approach to working with management teams — can mean the difference between a productive partnership and a missed connection. This guide is built from public sources and the firm's own stated philosophy, giving you a realistic picture of what they look for and how they operate.

RC Capital describes itself as "a business partner first and capital provider second." That framing matters. The firm does not see itself as writing checks and stepping back — it deploys significant human capital alongside capital, working closely with executives to navigate growth challenges. The 30-year track record of successes (and mistakes) informs every portfolio company's journey.

The healthcare sector presents unique complexities: regulatory landscapes, reimbursement pressures, clinical adoption curves. RC Capital's longevity in this space means they have seen the patterns before. They know which management teams can navigate FDA pathways, which go-to-market strategies scale in healthcare, and which metrics actually matter when evaluating a company's trajectory. That institutional knowledge is a core part of what they bring beyond the check.

RC Capital invests "on the right side of healthcare" — meaning they back companies that enable clinicians to do their jobs more effectively and improve the experiences and outcomes for patients. The firm has deliberately avoided the diagnostics and therapeutics side of healthcare in favor of the tools, services, and technology that make care delivery better. Understanding cash conversion cycles in healthcare is valuable for any founder.

Their thesis breaks into three interconnected segments: Medical Devices, Healthcare Services, and Healthcare IT. RC Capital looks for companies where the interplay between these segments creates a defensible competitive position — a medical device company with a services arm and an IT layer is harder to replicate than a pure device play. This multi-segment approach informs how they evaluate new investments and how they support existing portfolio companies.

In medical devices, RC Capital targets commercial-stage companies with high growth potential and strong gross margins that improve clinical outcomes while lowering the overall cost of care. The firm gravitates toward businesses relevant to Fortune 2000 med tech companies — either as strategic acquisition targets or as independent market leaders. Portfolio names like OrthAlign (surgical navigation for joint replacements), NICO (neurosurgery navigation and instrumentation), and Bolder Surgical (pediatric surgical devices) illustrate the types of companies they have backed in this space.

In healthcare services, the firm builds platforms in emerging markets by leveraging deep healthcare and technology expertise to add value and drive efficiencies in underserved care segments. The goal is always access, earlier diagnosis, and cost reduction. Urgent Team (urgent care), MindPath Health (mental health services), and OnCall Staffing (travel nursing) are representative of their services orientation.

In healthcare IT, RC Capital targets companies that drive efficiencies for payors and providers while engaging patients as consumers — all with the same outcome goal of improving care while lowering costs. Liquibase (database change management for enterprises), Canvas/GoCanvas (mobile field worker platforms), and Label Insight (consumer product intelligence) sit in this bucket, though Label Insight leans more consumer-packaged-goods-adjacent than pure healthcare.

The firm typically invests $5 million to $15 million per transaction in businesses generating at least $5 million in annual revenue. That positions them squarely in growth equity territory — past seed and Series A, into the phase where companies have demonstrated product-market fit and need capital to scale toward market leadership. They actively support portfolio companies through follow-on rounds as they grow.

The 2023 close of Fund VII marked a significant milestone for RC Capital. At $242 million (second close) with a $300 million target, it is the largest fund in the firm's 30-year history. The capital will continue RC Capital's established strategy: growth-stage healthcare companies in medical devices, services, and IT, deployed across the U.S. with a particular emphasis on the Midwest and Southeast given the firm's dual headquarters in Cincinnati and Raleigh. Understanding managing cash conversion cycles in deep tech is valuable for any founder.

The fundraise environment in 2023 was challenging for many GPs, but RC Capital's track record — 46 exits and a disciplined focus on a sector that has proven countercyclical — gave LPs confidence. Healthcare has remained a priority for institutional allocators, and a firm with RC Capital's tenure and reputation sits in a favorable position in a competitive fundraising landscape.

Active deployment from Fund VII is underway, with the firm maintaining its selectivity. Not every quality healthcare company will qualify — RC Capital's three-segment thesis and growth-stage focus create a specific profile. The firm continues to see deal flow through its network of healthcare executives, advisors, and co-investors, and warm introductions remain the most reliable path to a first meeting.

RC Capital's approach to portfolio support has matured alongside the firm. Senior partners are engaged directly with portfolio company leadership, not just at the board level but in operational planning, executive recruiting, and strategic pathway decisions. For founders who have not worked with an experienced growth equity partner, this level of engagement can be transformative — or intense, depending on how you prefer to operate.

RC Capital's portfolio spans 58 healthcare companies across the three focus segments. The following represent notable names across medical devices, services, and IT — companies that illustrate the firm's thesis and investment profile.

OrthAlign develops handheld surgical navigation systems for orthopedic procedures, most prominently used in total knee and hip replacements. Their technology enables more precise implant alignment, which correlates with better patient outcomes and fewer revision surgeries. The company has established itself as a differentiated player in a space where large med tech companies are actively acquiring navigation capabilities.

SPR Therapeutics offers a peripheral nerve stimulation platform for pain management — a non-opioid approach to chronic and acute pain that addresses a pressing clinical need. Their Sprint system has gained traction in sports medicine and orthopedics, targeting the massive post-surgical and injury-related pain market while avoiding the regulatory and societal risks of opioid-based approaches.

NICO (formerly NICO Corporation) provides minimally invasive neurosurgery technologies, including intracranial access systems and tumor resection tools. The company's approach reduces trauma compared to traditional neurosurgical approaches, improving patient recovery times and clinical outcomes in a field where precision is everything.

Bolder Surgical specializes in surgical devices for pediatric patients — an underserved market where device development requires different design thinking than adult-focused products. Their laparoscopic and imaging technology serves a niche with high barriers to entry and limited competition from major med tech players.

Urgent Team operates urgent care centers across the southeastern United States, providing a convenient alternative to emergency rooms for non-life-threatening conditions. This portfolio company illustrates RC Capital's services thesis: building platform businesses in fragmented markets where operational expertise can create scale advantages.

In healthcare IT, Liquibase (acquired by Datical, itself a RC Capital portfolio success) and Canvas (GoCanvas, acquired by Trimble) represent exits that delivered strong returns. These companies were built in healthcare-adjacent verticals but leveraged the firm's broader thesis around data management and field productivity. Label Insight and DialogTech are other names in the IT portfolio, each serving distinct market needs.

RC Capital's investment criteria reflect nearly 30 years of pattern recognition in healthcare growth companies. The firm looks first at the management team — founders and executives with deep sector knowledge, proven execution ability, and the self-awareness to know where they need support. Healthcare operates on long sales cycles, complex regulatory environments, and stakeholder-heavy decision-making, so experience matters in ways that do not always show up in pitch deck metrics.

Market opportunity has to be large and clearly defined. RC Capital is not interested in incremental improvements to existing workflows unless the total addressable market justifies the growth ambition. They prefer companies addressing problems in healthcare delivery where the pain is acute, the willingness to pay is established, and the competitive dynamics are not already settled by incumbents.

Business model quality is evaluated rigorously. RC Capital looks for companies that have moved beyond product-market fit validation into a true scaling phase — recurring revenue metrics, strong gross margins, and evidence that customer acquisition costs are sustainable as the company grows. For medical device companies, this often means established reimbursement codes and a growing base of health system customers. For services companies, it means unit economics that work at scale. For IT companies, it means low churn and expansion revenue.

Competitive positioning has to be defensible. RC Capital prefers businesses with some combination of proprietary technology (patents, trade secrets, clinical data), exclusive relationships (distribution partnerships, health system agreements), and brand moats (reputation, clinical evidence, customer loyalty). A pure software play with low switching costs will face more skepticism than one with embedded workflows that create real stickiness.

Finally, the alignment question matters: why this company, why now, and why does RC Capital specifically create the conditions for this business to win? A firm that has backed 58 healthcare companies over three decades has perspective on what works and what does not. Founders who come prepared with that context — understanding what RC Capital has seen, what they have learned, and where they add value beyond capital — stand out in the process.

The most effective path to RC Capital runs through a warm introduction. The firm works with healthcare executives, other VC and growth equity investors, and strategic partners who can vouch for a founder's credibility and the quality of the business. If you are building a healthcare company and have connections to health system executives, former RC Capital portfolio CEOs, or growth-stage investors who co-invest with the firm, leverage those relationships. The direct cold outreach path exists but is significantly slower.

If you do pursue a cold outreach, the pitch deck quality matters. RC Capital sees healthcare deals regularly, so generic market opportunity slides will not hold attention. Lead with the clinical problem, the specific solution, the traction you have achieved, and the business model that will scale. The firm is looking for companies that fit their three-segment framework — medical devices, services, or IT — so articulating where you fit within that thesis is important context.

When you earn a meeting, come prepared with detailed financials, clinical outcomes data if applicable, market sizing assumptions, and a clear growth trajectory. RC Capital's team will probe on reimbursement strategy for device companies, customer concentration for services companies, and churn dynamics for software companies. The due diligence process typically takes 4 to 8 weeks from initial meeting to term sheet, depending on deal complexity.

One underrated aspect of RC Capital's process: the firm values long-term relationship building. Even if your current round does not result in an investment, a company that demonstrates strong fundamentals and clear thinking may be revisited in future fundraises. Healthcare is a relationship-driven business, and the firm's partners are known for staying connected to founders across market cycles.

Explore the firm's website at https://rccf.com to learn more about their current portfolio, investment thesis, and team before reaching out. Demonstrating that you have done your homework on RC Capital specifically — not just generic healthcare VC outreach — will make an impression on their investment team.

RC Capital invests in growth-stage companies, which means they expect a level of financial sophistication that early-stage investors do not require. Before approaching the firm, make sure you have a clear handle on your revenue trajectory, gross margins, unit economics, and path to profitability or the next meaningful funding round. Founders who cannot articulate their financial model in clear terms will face skepticism from a team that has seen hundreds of healthcare businesses scale — or fail to.

Healthcare companies have specific financial dynamics that generalist investors may not understand: the cadence of reimbursement approvals, the capital equipment sales cycle, the lag between clinical trial data and commercial traction. If your business has these characteristics, be proactive in explaining them. Demonstrating that you understand the financial mechanics of your specific sector — not just that you have good top-line growth — will set you apart.

Working with a fractional CFO who has healthcare experience can meaningfully improve your fundraising positioning. A CFO partner who understands what growth-stage investors like RC Capital scrutinize — customer concentration, reimbursement risk, clinical data to support commercial claims — can help you present a financial narrative that is both accurate and compelling. They can also help you stress-test your model against realistic scenarios so you are not caught off guard in due diligence.

Our team has supported numerous healthcare companies through fundraising processes with growth equity firms. We understand the metrics RC Capital will focus on, the questions they will ask, and the financial presentations that resonate with healthcare-focused investors. If you are preparing for a conversation with RC Capital or a similar firm, we would be glad to help you get investor-ready.

Whether you are preparing to pitch RC Capital or another healthcare growth equity firm, professional financials and a compelling narrative about your path to market leadership are essential. The healthcare sector rewards companies that can demonstrate clinical differentiation alongside financial discipline. Build both, and you will have options.

Exploring other venture capital firms? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors, each written from real research rather than generic templates.

Each review provides detailed information about investment criteria, real portfolio companies, fund sizes, and sector-specific guidance for founders. Whether you are raising seed capital or growth equity, our library offers actionable intelligence on the investors most relevant to your business.

Healthcare founders should pay particular attention to funds with long track records in the sector — firms like RC Capital that have navigated multiple cycles bring a perspective that newer managers cannot replicate. Our reviews help you identify those differences and target your outreach strategically.